奥图穆马
医学
多发性硬化
内科学
复发-缓解
免疫学
美罗华
淋巴瘤
作者
Per Soelberg Sørensen,Steen Lisby,Richard Grove,Frederick J. Derosier,Steve Shackelford,Eva Havrdová,Jelena Drulović,Massimo Filippi
出处
期刊:Neurology
[Ovid Technologies (Wolters Kluwer)]
日期:2014-01-23
卷期号:82 (7): 573-581
被引量:270
标识
DOI:10.1212/wnl.0000000000000125
摘要
This study provides Class II evidence that in patients with RRMS, ofatumumab compared with placebo does not increase the number of serious adverse events and decreases the number of new MRI lesions.
科研通智能强力驱动
Strongly Powered by AbleSci AI